Fig. 4: TCRA2-2 and TCRA24 T cells eliminate CTNNB1S37F+ melanoma in vivo.
From: TCR-engineered T cells targeting a shared β-catenin mutation eradicate solid tumors
a, Schematic overview of the Mel888A24 + A2 + ffluc–eGFP CTNNB1S37F in vivo melanoma tumor model; n = 6–7 mice per group. Figure created with BioRender.com; 2 M, 2 million. b, BLI of Mel888A24 + A2 + ffluc–eGFP melanoma-engrafted mice on days –1, 1, 8, 27 and 101 after T cell injection. c,d, Survival analysis for each treatment group (c) and tumor size (d) measured by calipers in individual mice at the indicated time points after T cell injection. e, Percentage of hCD45+ T cells in mouse PB at the indicated time points (gating strategy in Extended Data Fig. 8a). Survival analysis in c was performed by log-rank (Mantel–Cox) test. Data in d and e are from one experiment, and each data point represents an individual mouse.
